GLP-1 Revolution
by Amaltash Advisors LLC
$146.01
+0.34% past month
Nov 16, 2026
$145.88-3.10%
The shares fell 3.10% on a day the broad market also fell, with the S&P 500 ETF (SPY) down 1.91% in the same session . The decline therefore came alongside a broad-market move, though it was steeper than the market's.
Nov 13, 2026
$150.55-0.43%
Nov 12, 2026
$151.20-3.27%
The company closed down 3.27%, while the broad market, measured by the S&P 500 ETF (SPY), fell only 0.35% on the same session . The move was therefore not shared by the broad market, which was close to flat by comparison .
Nov 11, 2026
$156.31+0.81%
Nov 10, 2026
$155.06-1.17%
Nov 9, 2026
$156.90+3.08%
The shares rose 3.08% on a day when the broad market also rose, with the S&P 500 ETF (SPY) up 2.37% in the same session . The move therefore came alongside a broad-market advance rather than apart from it .
Nov 6, 2026
$152.21+2.57%
The shares rose 2.57%, while the broad market, measured by the S&P 500 ETF, rose only 0.31% on the same session . The move was therefore largely not shared by the broad market .
Closing prices for XBI. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.
As of Nov 16, 2026, State Street SPDR S&P Biotech ETF is 14.0% below its 52-week high. Its largest decline in the period shown was -48.6% (Nov 18, 2021 to May 11, 2022).
As of Nov 16, 2026, State Street SPDR S&P Biotech ETF closed 14.0% below its 52-week closing high, set on Aug 19, 2026.
State Street SPDR S&P Biotech ETF fell 48.6% from Nov 18, 2021 to May 11, 2022, close to close, the largest decline in daily data since Nov 18, 2021. It closed back above that high on Nov 26, 2025.
Learn how max drawdown is measured, and how past market drawdowns played out.
Daily closing prices from Nov 18, 2021 to Nov 16, 2026, adjusted for splits but not dividends. Past price movements do not predict future results.
How much would it be worth today? $1,000 invested in State Street SPDR S&P Biotech ETF (XBI) 10 years ago, at the Nov 30, 2016 close, would be worth about $2,328 today, based on the Nov 16, 2026 close — a gain of $1,328 (+132.8%), dividends not included. Along the way it fell as much as 64.1% from a high, between Feb 2021 and May 11, 2022. Before Nov 2021 this uses monthly highs and lows.
Return calculator
Worth today, at the Nov 16, 2026 close
$21,058
+$8,158 · +63.2%The cash line is the same deposits earning nothing. A savings account would usually have paid some interest.
Past performance of XBI's closing prices (split-adjusted; dividends not included). It ignores fees, taxes and trading costs. The results change as prices update and with the amounts you enter. Past results do not predict future results, and a single stock can fall hard. We show this for every asset in our directory; it is not a recommendation to buy or sell XBI.
Try the full investment calculatorThe coffee test
A $5 coffee every workday comes to about $100 a month. Over 5 years that's 1,200 coffees, or $6,000.
The same $100 a month put into XBI since November 2021 would be worth $9,379 today.
That's 1,876 coffees. Make it a large.
Past performance, month-end prices. Not a forecast.
| Invested | Start date | XBI price then | $1,000 → | $10,000 → | Change |
|---|---|---|---|---|---|
| 1 year | Nov 28, 2025 | $123.16 | $1,184 | $11,845 | +18.4% |
| 3 years | Nov 30, 2023 | $75.52 | $1,932 | $19,317 | +93.2% |
| 5 years | Nov 30, 2021 | $116.27 | $1,255 | $12,547 | +25.5% |
| 10 years | Nov 30, 2016 | $62.67 | $2,328 | $23,277 | +132.8% |
$10,000 invested in State Street SPDR S&P Biotech ETF (XBI) at the Nov 30, 2016 close would have been worth about $23,277 at the Nov 16, 2026 close — a gain of $13,277 (+132.8%), dividends not included.
XBI closed at $62.67 on Nov 30, 2016 (split-adjusted). It closed at $145.88 on Nov 16, 2026.
Putting $100 into XBI at each month-end close from Nov 30, 2016 — 120 purchases, $12,000 in total — would have been worth about $18,963 at the Nov 16, 2026 close: a gain of $6,963 (+58.0%), dividends not included.
XBI closed at $145.88 on Nov 16, 2026. A year earlier it closed at $114.01 on Nov 14, 2025, so it is up 28.0% over that year. Five years earlier it closed at $124.81 on Oct 29, 2021 (up 16.9% since then). Its highest close in the year to Nov 16, 2026 was $169.55 on Aug 19, 2026, and its lowest was $113.83 on Nov 20, 2025. These are split-adjusted closing prices; dividends are not included.
XBI last closed at $145.88 on Nov 16, 2026. This page is updated once a day, so it does not show live prices.
Over one year, from $114.01 on Nov 14, 2025 to $145.88 on Nov 16, 2026, it was up 28.0%. Over five years, from $124.81 on Oct 29, 2021 to $145.88 on Nov 16, 2026, it was up 16.9%. These are split-adjusted closing prices; dividends are not included.
This fund holds stocks of U.S. biotech companies. It tracks the S&P Biotechnology Select Industry Index.
We do not tell anyone whether to buy or sell XBI, and past results do not predict future results. Its largest fall from a high since Nov 18, 2021 was 48.6%, from $122.22 on Nov 18, 2021 to $62.81 on May 11, 2022. A single fund can lose much of its value, so think about how much you could afford to lose. Our investment calculator shows how past amounts would have changed.
Past performance of XBI's closing prices. Not a forecast. This is general information, not a recommendation to buy or sell XBI.
Try the full investment calculatorThese strategies on Amaltash hold XBI today. We show them so you can see where it is used. This is not a recommendation to invest in any of them.
by Amaltash Advisors LLC